Cipla partners with Qilu to license, supply Keytruda biosimilar in US
Drug major Cipla Ltd on Thursday said its wholly owned subsidiary, Invagen Pharmaceuticals Inc, has entered into a strategic partnership with Qilu Pharmaceutical for the licensing and supply of a biosimilar to the cancer drug Keytruda in the United States. The product, QL2107, is a biosimilar to pembrolizumab (Keytruda) and aims to improve access to…
